What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health stock corrected after earnings because of the outlook on its key GLP-1 medication. See why I rate HIMS a ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) has earned a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two equities ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 1566.44 with a ...

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Explore what to expect now that the Hims & Hers stock price now that it has crashed hard in the past few weeks.

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...